ICON Public (ICLR) to Release Quarterly Earnings on Wednesday

ICON Public (NASDAQ:ICLR – Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, October 25th. Analysts expect the company to announce earnings of $3.10 per share for the quarter. ICON Public has set its FY23 guidance at $12.63-12.91 EPS and its FY 2023 guidance at $12.63-$12.91 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

ICON Public (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.92 by $0.04. ICON Public had a net margin of 6.45% and a return on equity of 11.21%. The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.02 billion. On average, analysts expect ICON Public to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

Get ICON Public alerts:

ICON Public Trading Down 3.1 %

Shares of ICLR stock opened at $237.48 on Wednesday. ICON Public has a 52-week low of $172.04 and a 52-week high of $268.07. The business’s fifty day moving average is $253.04 and its 200 day moving average is $232.93. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.22 and a current ratio of 1.22. The company has a market capitalization of $19.51 billion, a PE ratio of 39.31, a price-to-earnings-growth ratio of 1.36 and a beta of 1.12.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ICLR shares. Mizuho reissued a “buy” rating and set a $274.00 price objective on shares of ICON Public in a report on Wednesday, September 13th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of ICON Public from $280.00 to $300.00 in a research note on Friday, July 14th. Barclays raised their price objective on shares of ICON Public from $250.00 to $280.00 and gave the company an “overweight” rating in a research report on Friday, July 28th. StockNews.com initiated coverage on shares of ICON Public in a research report on Thursday, October 5th. They issued a “hold” rating for the company. Finally, TD Cowen assumed coverage on ICON Public in a research note on Wednesday, September 13th. They set an “outperform” rating and a $306.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and a consensus target price of $271.50.

Read Our Latest Stock Report on ICON Public

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Tennessee Treasury Department boosted its holdings in ICON Public by 2.4% during the 2nd quarter. State of Tennessee Treasury Department now owns 110,747 shares of the medical research company’s stock valued at $27,709,000 after acquiring an additional 2,605 shares during the period. SkyView Investment Advisors LLC boosted its stake in shares of ICON Public by 4.4% during the second quarter. SkyView Investment Advisors LLC now owns 2,505 shares of the medical research company’s stock valued at $627,000 after purchasing an additional 105 shares during the period. Captrust Financial Advisors grew its holdings in shares of ICON Public by 5.4% in the second quarter. Captrust Financial Advisors now owns 26,948 shares of the medical research company’s stock worth $6,742,000 after purchasing an additional 1,376 shares during the last quarter. KB Financial Partners LLC increased its stake in shares of ICON Public by 3.6% in the second quarter. KB Financial Partners LLC now owns 2,562 shares of the medical research company’s stock worth $641,000 after buying an additional 88 shares during the period. Finally, First Horizon Advisors Inc. raised its holdings in ICON Public by 10.9% during the 1st quarter. First Horizon Advisors Inc. now owns 551 shares of the medical research company’s stock valued at $118,000 after buying an additional 54 shares during the last quarter. 95.21% of the stock is owned by institutional investors.

ICON Public Company Profile

(Get Free Report)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Articles

• Five stocks we like better than ICON Public
• 10 Best Airline Stocks to Buy
• Analysts Recommend These Stocks To Cushion The Automotive Slump
• How Can Investors Benefit From After-Hours Trading
• Hyatt Hotels Earning Analysts Love, Buy The Dip?
• What is the Euro STOXX 50 Index?
• Business is Good for Lockheed Martin; Shares are Ready to Soar.

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.